Literature DB >> 23489585

Liver cancer incidence and mortality in China, 2009.

Wan-Qing Chen1, Rong-Shou Zheng, Si-Wei Zhang.   

Abstract

Liver cancer is a common cancer and a leading cause of cancer deaths in China. To aid the government in establishing a control plan for this disease, we provided real-time surveillance information by analyzing liver cancer incidence and mortality in China in 2009 reported by the National Central Cancer Registry. Liver cancer incidence and cases of death were retrieved from the national database using the ICD-10 topography code "C22". Crude incidence and mortality were calculated and stratified by sex, age, and location (urban/rural). China's population in 1982 and Segi (world) population structures were used for age-standardized rates. In cancer registration areas in 2009, the crude incidence of liver cancer was 28.71/100,000, making it the fourth most common cancer in China, third most common in males, and fifth most common in females. The crude mortality of liver cancer was 26.04/100,000, making it the second leading cause of cancer death in China and urban areas and the third leading cause in rural areas. Incidence and mortality were higher in males than in females and were higher in rural areas than in urban areas. The age-specific incidence and mortality were relatively low among age groups under 30 years but dramatically increased and peaked in the 80-84 years old group. These findings confirm that liver cancer is a common and fatal cancer in China. Primary and secondary prevention such as health education, hepatitis B virus vaccination, and early detection should be carried out both in males and females, in urban and rural areas.

Entities:  

Mesh:

Year:  2013        PMID: 23489585      PMCID: PMC3845572          DOI: 10.5732/cjc.013.10027

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


Liver cancer is a common and fatal cancer in the world. According to world cancer statistics, 749,000 new cases were diagnosed and 695,000 deaths were reported in 2008[1]. In China, liver cancer has been the second leading cause of cancer death since the 1990s[1]. Time trend analysis showed that the crude incidence of liver cancer is increasing, and a slight downward trend has been observed over the last 20 years after adjusted by age. The National Central Cancer Registry (NCCR) of China is the government organization in charge of collecting cancer information nationwide and reporting cancer statistics annually. Since 2008, the Chinese Cancer Registry annual report has provided cancer incidence and mortality data with which to create strategies for cancer prevention and control. In 2012, NCCR collected data for the calendar year of 2009 from 104 registries. After comprehensive quality control, data from 72 registries were accepted as sources of the annual report to reflect cancer incidence and mortality in the registration areas in 2009. In this study, liver cancer cases were retrieved from the national database for analysis.

Materials and Methods

Data source

All new cancer cases diagnosed in 2009 were reported to local cancer registries from all hospitals, community health centers, and the other departments, including centers of township medical insurance and the New-type Rural Cooperative Medical System. Vital statistics were linked and matched with the cancer registration database for identifying cancer deaths and missed cases. For all 104 cancer registries (46 cities and 58 counties from 27 provinces) reporting cancer registration data to NCCR, the overall population coverage was 109,476,347, accounting for 8.20% of the whole population in 2009. The cancer registries coded cancer site and histology according to the International Classification of Diseases for Oncology, third edition (ICD-03) and tenth edition (ICD-10). Invasive cases of liver cancer (topography code as C22) were retrieved from the NCCR database and analyzed. Demographic information was provided by the National Statistics Bureau.

Quality control

Based on “Guideline of Chinese Cancer Registration” and the standard of data inclusion in “Cancer Incidence in Five Continents Volume IX”[2], cancer registration data were evaluated by the following quality indicators: proportion of morphologic verification (MV%), percentage of cancer cases identified with death certification only (DCO%), and mortality-to-incidence ratio (M/I)[3]–[5]. The detailed standard for data inclusion was shown previously[6]. Generally, data with DCO% less than 20%, overall MV% more than 55%, and M/I between 0.55 and 0.95 were considered acceptable.

Statistical analysis

Crude incidence and mortality of liver cancer were calculated by sex, area, and for 19 total age groups (<1, 1–4, 5–9, … 80–84, ≥85 years). Age-standardized rates were calculated using the Chinese population in 1982 and Segi (world) population. The cumulative risk of developing or dying from cancer before 75 years of age (in the absence of competing causes of death) was calculated and presented as a percentage. Software including MS-FoxPro, MS-Excel, and IARCcrgTools issued by International Agency for Research on Cancer (IARC) and International Association of Cancer Registry (IACR) were used for data checkup. SAS software was used to calculate the incidence and mortality rates.

Results

Pooled data

Data from 72 population-based cancer registries were accepted for the annual report after evaluation based on quality control criteria. The population covered by these cancer registries was 85,470,522, including 43,231,554 males and 42,238,968 females, accounting for 6.40% of the whole national population. A total of 31 registries were from urban areas, covering a total population of 57,489,009, and 41 registries were from rural areas, covering a total population of 27,981,513. The MV%, DCO%, and M/I of liver cancer for the national pooled data were 34.10%, 5.91%, and 0.91, respectively. The MV%, DCO%, and M/I were 38.11%, 6.08%, and 0.91, respectively, in urban areas and 27.46%, 5.63%, and 0.91, respectively, in rural areas. There were 24,536 new cases of liver cancer (18,155 males and 6,381 females) and 22,255 liver cancer deaths (16,409 males and 5,846 females) in 2009. Population and liver cancer incidence and deaths in each cancer registry are shown in Table 1.
Table 1.

Population and number of new liver cancer cases and deaths in cancer registries in 2009

RegistryAreaPopulation
New cancer cases
Cancer death
BothMaleFemaleBothMaleFemaleBothMaleFemale
BeijingUrban7,645,1863,859,5863,785,6001,4981,0934051,323970353
QianxiRural361,312182,138179,174896821665115
ShexianRural394,944205,168189,776804931806119
CixianRural634,333322,621311,71210369341017229
BaodingUrban948,612478,051470,5611611035818010476
YangquanUrban683,165346,023337,1421097237926131
YangchengRural383,165192,119191,04613384491308446
ChifengUrban1,203,006613,725589,28146034311735526095
ShenyangUrban3,497,8151,722,9761,774,839796567229803590213
DalianUrban2,266,2241,136,7721,129,452713547166622458164
ZhuangheRural915,660461,826453,8342621897328420381
An'shanUrban1,471,775731,916739,859446327119400291109
BenxiUrban955,409475,113480,2962752066928221864
DandongUrban767,011378,794388,21731721210526619571
DonggangRural640,853323,798317,0553332359821815761
DehuiRural943,395479,486463,9092281587022815771
YanjiRural440,957215,260225,6971461212513110328
Daoli District, HarbinUrban713,264351,071362,1932101535717012149
Nangang District, HarbinUrban1,020,233508,921511,3122301666421716354
ShangzhiRural616,046314,864301,1822511678416611155
ShanghaiUrban6,181,3343,084,4963,096,8381,7291,2255041,5931,151442
JintanRural545,000262,407282,5938860281198534
SuzhouUrban2,392,0871,183,7161,208,371619445174545378167
HaianRural936,785463,612473,17336125011133223795
QidongRural1,114,951548,805566,146843611232783569214
HaimenRural1,016,228501,407514,821544415129506373133
LianyungangUrban886,862452,358434,5041941544020415549
DonghaiRural1,117,858579,751538,1072682016722016852
GuanyunRural1,015,229534,502480,7273512619033325578
Chuzhou District, Huai'anUrban1,174,877609,088565,7892812126920615254
Huaiyin District, Huai'anUrban900,027465,502434,5252682145424919752
XuyiRural759,450388,180371,2702391726719014050
JinhuRural352,292176,689175,603775720706010
SheyangRural965,817494,682471,135415302113379270109
JianhuRural805,465410,369395,0962001633719415836
DafengRural724,147363,326360,8212641917322917257
YangzhongRural272,046134,758137,288483315554114
TaixingRural1,128,840613,199515,64145335010340531590
HangzhouUrban6,753,5093,403,8933,349,6162,0561,5335231,9741,430544
JiaxingUrban509,367253,819255,54813994451309040
JiashanRural382,475189,692192,7831531064716010951
HainingRural653,957322,969330,988146100461399247
ShangyuRural771,321383,462387,8592822235928221765
XianjuRural490,070255,438234,6321771413618314934
FeixiRural858,895449,882409,0131451212415411341
MaanshanUrban633,477323,834309,643125105201139023
TonglingUrban433,545221,375212,170674423644717
ChangleRural673,717355,091318,6261941484613310330
XiamenUrban1,160,135583,873576,2624153397639331281
Zhanggong District, GanzhouUrban420,759212,159208,6001741452914811038
LinquRural817,857417,434400,4232141437121015753
WenshangRural762,828388,454374,374114852915311241
FeichengRural733,501358,739374,7621751235214110140
YanshiRural602,266306,192296,07411981381006436
LinzhouRural1,080,241557,392522,84914798491399643
XipingRural858,002434,899423,1032791899025417480
WuhanUrban4,832,1742,484,6222,347,5521,211933278941722219
YunmengRural524,801261,237263,5641551055018813355
HengdongRural713,458373,923339,5352351795614911336
GuangzhouUrban3,968,2162,014,5801,953,6361,3201,0432771,242951291
SihuiRural413,363211,351202,0121641273714010931
ZhongshanUrban1,468,391732,333736,0583432885530025050
LiuzhouUrban1,038,208533,050505,1583472777025019753
FusuiRural444,332236,000208,3323112565523919544
Jiulongpo District, ChongqingUrban798,618402,961395,6571491173218914544
Qingyang District, ChengduUrban534,701277,154257,54712090301078324
Ziliujing District, ZigongUrban357,600179,873177,727138109291017823
YantingRural610,103316,499293,60431621310328019090
JingtaiRural233,609119,953113,656613823543618
Liangzhou District, WuweiUrban990,583524,276466,3071821285429721087
XiningUrban882,839439,175443,664215141741298940
XinyuanRural271,944138,895133,049664818533617
Total85,470,52243,231,55442,238,96824,53618,1556,38122,25516,4095,846

Incidence

The crude incidence of liver cancer was 28.71/100,000 in 2009, accounting for 10.04% of overall new cancer cases and ranking fourth in all cancer sites. The age-standardized incidences by the Chinese population (ASIRC) and world population (ASIRW) were 14.78/100,000 and 19.28/100,000, respectively. Among persons under the age of 75, the cumulative incidence was 2.20%. Liver cancer occurred more often in males than in females. For males, liver cancer was the third most common cancer, with a crude incidence of 41.99/100,000, whereas the ASIRC and ASIRW were 22.49/100,000 and 29.17/100,000, respectively. For females, liver cancer was the fifth most common cancer, with a crude incidence of 15.11/100,000, whereas the ASIRC and ASIRW were 7.11/100,000 and 9.52/100,000, respectively. The crude incidence in urban areas (26.63/100,000) was lower than that in rural areas (32.98/100,000) but ranked fourth in both areas. After age standardization, the incidence in urban areas (ASIRW = 17.18/100,000) was still lower than that in rural areas (ASIRW = 24.04/100,000) (Table 2).
Table 2.

Liver cancer incidence by sex and area in registration areas in 2009

LocationSexNo. of casesCrude incidence (1/105)Percentage (%)ASIRC (1/105)ASIRW (1/105)Cumulative rate (%) Age 0–74Ranka
All areasBoth24,53628.7110.0414.7819.282.204
Male18,15541.9913.2122.4929.173.313
Female6,38115.115.977.119.521.115
UrbanBoth15,30726.638.7813.1317.181.954
Male11,42539.4211.9420.3226.432.983
Female3,88213.624.936.058.150.945
RuralBoth9,22932.9813.1918.5224.042.774
Male6,73047.2416.1227.3335.264.034
Female2,49918.198.869.5712.701.485

aThe proportion rank of liver cancer in all cancer types.

ASIRC, age-standardized incidence by Chinese population; ASIRW, age-standardized incidence by world population.

The age-specific incidence was relatively low in subjects under 30 years old but dramatically increased in those over 30, peaking in the 80–84 years old group in both males and females. Notably, after the age of 30, incidence in males was more than double that in females, although there were slight differences among those under 30. The age-specific liver cancer incidence in urban areas was generally lower than that in rural areas both in males and females, especially in older age groups (Table 3, Figure 1).
Table 3.

Age-specific incidences of liver cancer in cancer registration areas in 2009

Age groupAll areas
Urban areas
Rural areas
BothMaleFemaleBothMaleFemaleBothMaleFemale
All28.7141.9915.1126.6339.4213.6232.9847.2418.19
0–1.131.530.681.301.990.550.850.790.91
1–0.440.550.310.650.900.370.100.000.21
5–0.140.160.120.140.180.100.130.130.14
10–0.180.170.180.230.220.240.100.100.11
15–0.310.570.040.280.550.000.370.610.11
20–0.730.870.590.610.780.441.021.100.94
25–1.532.660.371.342.190.451.983.720.18
30–5.188.391.914.747.791.655.979.472.40
35–11.5119.823.109.5316.492.5115.4526.414.28
40–21.8236.317.0217.9030.285.2929.6948.3710.51
45–30.8150.4010.5027.5746.278.0938.1259.7615.89
50–49.5079.5518.5142.4970.0614.2067.34103.4729.59
55–60.6595.1825.9052.9685.5120.7779.03117.5838.52
60–71.62106.2036.9363.4796.5431.0689.24126.3050.10
65–84.24119.8849.4375.07109.9441.97102.52138.8764.95
70–101.76140.1466.4992.66127.1361.53123.65170.4978.76
75–121.72164.5883.63114.57155.9777.44140.27187.3599.46
80–133.99182.7495.30131.10180.8590.66141.29187.76106.61
85–119.44165.7690.12119.04166.3588.33120.48164.1394.63

All values are presented as incidence (1/100,000).

Figure 1.

Age-specific incidence of liver cancer in males and females in urban and rural areas in 2009.

The age-specific incidence kept increasing with the age increase and reached at peak in the 80–84 years old group. Incidences in rural areas were higher than those in urban areas and incidences in males were higher than those in females in any age group.

aThe proportion rank of liver cancer in all cancer types. ASIRC, age-standardized incidence by Chinese population; ASIRW, age-standardized incidence by world population.

Mortality

The crude mortality for liver cancer was 26.04/ 100,000 in 2009, accounting for 14.42% of overall cancer deaths in 2009. The ASMRC and ASMRW for mortality were 13.06/100,000 and 17.26/100,000, respectively. Among patients at 0–74 years of age, the cumulative mortality was 1.96%. The mortality was higher in males than in females. The crude mortality, ASMRC, and ASMRW were 37.96/100,000, 19.91/100,000, and 26.14/100,000, respectively, for males and 13.84/100,000, 6.28/100,000, and 8.54/100,000, respectively, for females. These values were 24.15/100,000, 11.51/100,000, and 15.27/100,000, respectively, in urban areas and 29.91/100,000, 16.54/100,000, and 21.72/100,000, respectively, in rural areas. Liver cancer was ranked the second leading cause of cancer death in urban and third in rural areas (Table 4, Figure 2).
Table 4.

Liver cancer mortality in cancer registration areas in 2009

LocationSexNo. of casesCrude mortalty (1/105)Percentage (%)ASMRC (1/105)ASMRW (1/105)Cumulative rate (%) Age 0–74Ranka
All areasBoth22,25526.0414.4213.0617.261.962
Male16,40937.9616.9319.9126.142.952
Female5,84613.8410.196.288.540.993
UrbanBoth13,88524.1513.2811.5115.271.722
Male10,26835.4315.8517.7623.402.622
Female3,61712.699.095.397.380.844
RuralBoth8,37029.9116.8216.5421.722.503
Male6,14143.1119.1024.6532.173.663
Female2,22916.2312.668.3411.221.324

aThe proportion rank of liver cancer in all cancer types.

ASMRC, age-standardized mortality by Chinese population; ASMRW, age-standardized mortality by world population.

Figure 2.

Age-specific mortality of liver cancer in males and females in urban and rural areas in 2009.

The age-specific mortality kept increasing with the age increase and reached at peak in the 80–84 years old group except for urban females. Mortalities in rural areas were higher than those in urban areas and mortalities in males were higher than those in females in any age group.

Mortality was relatively low in age groups under 35 and peaked in the 80–84 year old age group in overall areas and urban areas. In rural areas, mortality in the over 85 age group was the highest among all age groups. After the age of 15, age-specific mortality was higher in rural areas than in urban areas and was higher in males than in females (Table 5).
Table 5.

Age-specific mortality of liver cancer in cancer registration areas in 2009

Age groupAll areas
Urban areas
Rural areas
BothMaleFemaleBothMaleFemaleBothMaleFemale
All26.0437.9613.8424.1535.4312.6929.9143.1116.23
0–0.480.610.340.781.000.550.000.000.00
1–0.370.420.310.470.680.250.190.000.41
5–0.080.110.060.050.090.000.130.130.14
10–0.040.040.050.040.070.000.050.000.11
15–0.240.390.080.140.280.000.420.610.22
20–0.570.740.390.500.670.320.740.920.56
25–1.021.630.390.881.290.451.352.390.27
30–3.275.461.032.684.540.804.327.121.46
35–8.8014.892.637.5012.622.3511.3819.383.21
40–17.3829.215.3113.5522.864.0725.0941.937.80
45–26.4944.158.1723.6540.196.4132.9053.1212.12
50–41.9867.9515.2136.1760.0411.6956.7787.9024.24
55–51.6182.2020.8144.5072.8216.5168.59103.9531.43
60–63.4895.1431.7153.9882.4326.1183.99121.5944.29
65–78.18111.3145.8268.96100.0139.4996.53132.8858.97
70–99.36136.4865.2591.48126.2260.09118.33160.4178.00
75–125.44172.5083.63119.39163.0580.22141.18197.5092.36
80–144.15200.4799.46143.42202.2195.62146.01195.86108.81
85–136.80187.58104.66134.64184.60102.21142.44195.81110.83

All values are presented as mortality (1/100,000).

All values are presented as incidence (1/100,000).

Age-specific incidence of liver cancer in males and females in urban and rural areas in 2009.

The age-specific incidence kept increasing with the age increase and reached at peak in the 80–84 years old group. Incidences in rural areas were higher than those in urban areas and incidences in males were higher than those in females in any age group. aThe proportion rank of liver cancer in all cancer types. ASMRC, age-standardized mortality by Chinese population; ASMRW, age-standardized mortality by world population.

Age-specific mortality of liver cancer in males and females in urban and rural areas in 2009.

The age-specific mortality kept increasing with the age increase and reached at peak in the 80–84 years old group except for urban females. Mortalities in rural areas were higher than those in urban areas and mortalities in males were higher than those in females in any age group.

Discussion

For this analysis of liver cancer incidence and mortality, we assessed data from 72 cancer registries covering 85.47 million people from 27 provinces—the largest population coverage since NCCR started to publish annual reports in 2008. We found that there were 24,536 new cases and 22,255 deaths from liver cancer. Although a large sample size was included in this study, further representative analysis should follow. In terms of quality control, morphologic verification for liver cancer is relatively low compared with other cancers, especially in rural areas, because medical resources are limited and pathologic examination cannot always be performed (e.g., for late-stage liver cancer). In global data, the MV% of liver cancer fluctuated markedly among different countries and registries[7]. The national cancer registry program was established by the Ministry of Health in 2008, providing grants from central finance to build a national cancer registry network. The number of cancer registries has increased from 43 in 2007 to 222 in 2012, with the covered population reaching 200 million. It is estimated that there will be more than 300 registries covering 20% of the national population by the end of 2015. All values are presented as mortality (1/100,000). Compared with the results in 2008[8], the crude incidence and mortality fluctuated slightly in 2009 due to different population coverage. However, after adjusting for age, the rates remained stable, reflecting the good quality of the registration data[6]. Chen et al. reported that there were 339,000 incident cases of liver cancer in China in 2005[9] and predicted that number would reach 381,000 in 2020[10]. Recent trend analysis showed that although age-adjusted incidence has decreased, the liver cancer burden is increasing[11]. China is a high-risk region for liver cancer, representing more than half of new cases and liver cancer deaths in the world[12]. Since high-risk areas like Qidong in Jiangsu province implemented hepatitis B virus (HBV) vaccination for children, the HBV infection rate has fallen, reducing the incidence of liver cancer in the young generation. Early in the 21st century, when expanded program immunization was carried out in China, hepatitis B was effectively controlled, providing a benefit for liver cancer control[13],[14]. In Qidong, liver cancer screening programs were introduced in 2006[15]. Similarly, some high-risk areas gradually started early detection and treatment for liver cancer. HBV vaccination and screening as well as health education and promotion have become areas of focus for high-risk areas in China. In conclusion, although the incidence of liver cancer has started to decrease in most age groups, especially in the young generation, it is still a major public issue in China. The cancer registry provides timely and dynamic information for making national, regional, and local policies for cancer control. As NCCR continues to expand the national cancer registry system, primary and secondary prevention of liver cancer is expected to improve.
  8 in total

1.  [Evaluation of secular trend of liver cancer incidence in Qidong, Jiangsu province, 1973-2002].

Authors:  Jian-guo Chen; Jian Zhu; Yong-hui Zhang; Yuan-rong Zhu; Jian-hua Lu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2005-11-16

2.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

3.  [Estimation of cancer incidence and mortality in China in 2004-2005].

Authors:  Wan-qing Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2009-09

4.  [An analysis of lung cancer mortality in China, 2004 - 2005].

Authors:  Wan-qing Chen; Si-wei Zhang; Xiao-nong Zou; Ping Zhao
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2010-05

5.  [A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China].

Authors:  Jian-guo Chen; Jian-hua Lu; Yuan-rong Zhu; Jian Zhu; Yong-hui Zhang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2010-07

Review 6.  Liver cancer epidemic in China: past, present and future.

Authors:  Jian Guo Chen; Si Wei Zhang
Journal:  Semin Cancer Biol       Date:  2010-12-07       Impact factor: 15.707

7.  Screening for liver cancer: results of a randomised controlled trial in Qidong, China.

Authors:  J-G Chen; D M Parkin; Q-G Chen; J-H Lu; Q-J Shen; B-C Zhang; Y-R Zhu
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

8.  [Estimation and projection of lung cancer incidence and mortality in China].

Authors:  Wanqing Chen; Siwei Zhang; Xiaonong Zou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-05
  8 in total
  30 in total

1.  Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance.

Authors:  Kunpeng Hu; Jiani Wang; Zhicheng Yao; Bo Liu; Yuan Lin; Lei Liu; Lihua Xu
Journal:  Med Oncol       Date:  2014-03-30       Impact factor: 3.064

2.  NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.

Authors:  Li-Li Liu; Mei-Fang Zhang; Ying-Hua Pan; Jing-Ping Yun; Chris Zhiyi Zhang
Journal:  Tumour Biol       Date:  2014-02-25

3.  Functional polymorphisms of circadian negative feedback regulation genes are associated with clinical outcome in hepatocellular carcinoma patients receiving radical resection.

Authors:  Zhaohui Zhang; Fei Ma; Feng Zhou; Yibing Chen; Xiaoyan Wang; Hongxin Zhang; Yong Zhu; Jianwei Bi; Yiguan Zhang
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

4.  Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.

Authors:  Haili Huang; Min Hu; Peng Li; Caijie Lu; Mingyi Li
Journal:  Tumour Biol       Date:  2014-10-15

5.  Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance.

Authors:  Jingmei Ye; Jiani Wang; Li Tan; Shaojiang Yang; Lihua Xu; Xiaohong Wu; Huaifu Deng; Huo Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

6.  The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.

Authors:  Ling Lin; Yang-de Zhang; Zi-Yu Chen; Yuxiang Chen; Cai-Ping Ren
Journal:  Tumour Biol       Date:  2016-06-14

7.  Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest.

Authors:  Nan Li; Donghai Zheng; Jie Xue; Weixing Guo; Jie Shi; Juxian Sun; Chongde Lu; Weida Zheng; Mengchao Wu; Shuqun Cheng
Journal:  Exp Ther Med       Date:  2015-03-13       Impact factor: 2.447

8.  Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model.

Authors:  Chen Ling; Yuan Wang; Yuanhui Zhang; Anila Ejjigani; Zifei Yin; Yuan Lu; Lina Wang; Meng Wang; Jun Li; Zhongbo Hu; George V Aslanidi; Li Zhong; Guangping Gao; Arun Srivastava; Changquan Ling
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

9.  Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening.

Authors:  Ka Yin Lui; Hao-Ran Peng; Jin-Rong Lin; Chun-Hui Qiu; Hu-An Chen; Rong-Dang Fu; Chang-Jie Cai; Min-Qiang Lu
Journal:  Tumour Biol       Date:  2015-08-20

10.  microRNA-506 regulates proliferation, migration and invasion in hepatocellular carcinoma by targeting F-spondin 1 (SPON1).

Authors:  Wei Dai; Hai-Li Huang; Min Hu; Si-Jie Wang; Hui-Juan He; Nian-Pin Chen; Ming-Yi Li
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.